Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette Sells 638 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Roland Goette also recently made the following trade(s):

• On Friday, December 6th, Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $221.01, for a total value of $990,787.83.

Becton, Dickinson and Company Trading Down 0.7 %

Shares of Becton, Dickinson and Company stock opened at $221.35 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock has a market capitalization of $64.00 billion, a P/E ratio of 37.26, a P/E/G ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The stock’s 50-day simple moving average is $232.24 and its 200 day simple moving average is $233.54.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.42 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is presently 63.97%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. Benson Investment Management Company Inc. grew its holdings in shares of Becton, Dickinson and Company by 13.2% during the third quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after purchasing an additional 2,602 shares in the last quarter. Swedbank AB grew its holdings in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after purchasing an additional 2,729 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its holdings in shares of Becton, Dickinson and Company by 2.3% during the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock worth $135,267,000 after purchasing an additional 12,845 shares in the last quarter. Finally, Curi RMB Capital LLC grew its holdings in shares of Becton, Dickinson and Company by 18.1% during the third quarter. Curi RMB Capital LLC now owns 84,873 shares of the medical instruments supplier’s stock worth $20,463,000 after purchasing an additional 13,030 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research reports. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.